An International Survey on the Use of a Polyrevitalizing Solution With or Without Other Aesthetic Procedures in the Daily Practice of Aesthetic Physicians

Abstract

Objective: NCTF135HA, a versatile polyrevitalizing solution, is a potent agent for enhancing skin quality, radiance, moisture, vitality, and diminishing fine wrinkles caused by aging factors. Data demonstrate a divergence in its application from skin quality enhancement to treatment of vitiligo lesions. To know more precisely about the protocol of use among providers, alone or in combination with other procedures, we performed an international survey.

Method: A Steering Committee of dermatologists, aesthetic surgeons, and physicians developed a 32-question questionnaire based on a literature review. Hosted online from January to March 2024, it targeted healthcare professionals experienced in polyrevitalization. Responses were analyzed anonymously and reported descriptively.

Results: Practitioners adopt a balanced approach: half of their patients receiving classic Polyrevitalization (NCTF135HA alone) and the other half undergoing combination therapy (NCTF135HA with another aesthetic procedure). Most administer NCTF135HA across multiple sessions, typically three (39.7%). In combination therapy, 55.5% of practitioners use NCTF135HA for medical purposes, targeting Melasma (53.1%) and Rosacea (45.0%) for instance. Aesthetic use is prevalent, with 94.2% employing NCTF135HA for skin wrinkles (79.9%), and refreshment, rejuvenation, and hydration (73.4%). Combining NCTF135HA with hyaluronic acid (71.2%) and botulinum toxin (49.1%) is common, alongside microneedling (50.2%), peelings (32.4%), and fractional radiofrequency (25.6%).

Limitations and conclusion: Our survey showed a homogenous distribution of NCTF135HA utilization, indicating a consensus on its application across diverse demographics. This consistency highlights its widespread acknowledgment and efficacy in various aesthetic and clinical settings. Limitations include a large respondent group from Mexico and many respondents with less than 10 years of experience.

Keywords: NCTF135HA; Polyrevitalization; combination therapy.

FIGURE 1

NCTF135HA use in practice. (A) Distribution of the use in classic polyrevitalization and/or in combination therapy (n = 371; single choice question); (B) Number of patients put on classical polyrevitalization and on combination therapy among 10 interventions (n = 278; open‐field response); (C) Reasons for not combining NCTF135HA (n = 178; open‐field response).

FIGURE 2

NCTF135HA in combination for medical purposes. (A) Percentage of respondents using NCTF135HA in combination for medical purposes (n = 292; single‐choice question); (B) Indications for the use of NCTF135HA in combination for medical purposes (n = 160; multiple‐choice question), Other: Alopecia, skin treatment, skin aging, scars treatment, and dermatologic treatment.

FIGURE 3

NCTF135HA used in combination for aesthetic procedures. (A) Percentage of respondents who are combing NCTF135HA for aesthetic procedures (n = 296; single‐choice question); (B) Reasons to combine NCTF135HA for aesthetic procedures (n = 227; multiple‐choice question), Other: “Improving the response of the bio‐scaffold by creating a better extracellular matrix environment”; (C) Indications for aesthetic procedures in which NCTF135HA is combined (n = 229; multiple‐choice question), Other(s): Epidermal cell remodeling; (D) Areas treated with NCTF135HA in combination therapy (n = 232; multiple‐choice question); (E) Body areas treated with NCTF135HA in combination therapy (n = 215; multiple‐choice question), Other(s): Lips and vuvla.

FIGURE 4

NCTF135HA frequency and volume. (A) Number of sessions to inject NCTF135HA in combination therapy for aesthetic purposes (n = 199; multiple‐choice response); (B) Frequency of the sessions (n = 278; multiple‐choice question), Other: Up to 6 weeks, up to 8 weeks, up to 3 months, Day 0, 15, 15, 1 month later, 1 month later, the first two sessions every 2 weeks, and the following 3 sessions every 4 weeks; (C) Number of NCTF135HA vials used for the face (n = 238; multiple‐choice question), Other: 1 to 2 mL, it depends on the protocol; (D) Number of NCTF135HA vials used for the body (n = 152; multiple‐choice question).

FIGURE 5

NCTF135HA combination with injectable products. (A) Type of injectable products used in combination therapy for aesthetic purposes (=226; multiple‐choice question), Other: Smooth polydioxane threads; (B) Volume of NCTF135HA used with different injectable products (n = 118; open‐field response), Other: 1 to 3 mL with PRP, 1 mL for 20 mL of fat, 1 mL with peptides, 2 mL with Aquagold, 2 mL with polynucleotides; (C) Type of instruments used to inject (n = 231; multiple‐choice question), Other: Mesotherapy needles.

FIGURE 6

NCTF135HA in combination therapy with technologies. (A) Technologies used in NCTF135HA combination therapy (n = 219; multiple‐choice question), Other(s): Microfocused ultrasound, laser technology (Diode endolaser, K laser, Intense pulse light), Aquagold and Jett plasma; (B) NCTF135HA injection protocol for combination with energy‐based devices (n = 204; multiple‐choice response).

FIGURE 7

NCTF135HA combination with surgery. (Multiple‐choice question; Other: Labioplasty, vulvar harmonization, Brazilian Butt Lift/Fat Graft).